Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)

Seminars in Oncology

Volumn 32, Issue SUPPL. 5, 2005, Pages 11-15

  Fenaux, Pierre ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HEMOGLOBIN;

BLEEDING TENDENCY; CHEMICAL CARCINOGENESIS; CHROMOSOME ABERRATION; CIGARETTE SMOKING; CYTOPENIA; DNA METHYLATION; GENE OVEREXPRESSION; GENETIC EPIGENESIS; HEMOGLOBIN DETERMINATION; HUMAN; INDUCED MUTATION; MEDICAL ASSESSMENT; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 23444457951     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.06.016     Document Type: Article

References (25)

1. W.-K. Hofmann, M. Lübbert, D. Hoelzer Myelodysplastic syndromes Hematol J 5 2004 1 8
2. Mufti G, List AF, Gore SD,, et al. Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program) 176-199, 2003
3. H. Maschek, V. Kaloutsi, M. Rodriguez-Kaiser Hypoplastic myelodysplastic syndrome: Incidence, morphology, cytogenetics, and prognosis Ann Hematol 66 1993 117 122
4. E. Hellström-Lindberg Treatment of adult myelodysplastic syndromes Int J Hematol 70 1999 141 154
5. S.M. Dunkley, A. Manoharan, Y.L. Kwan Myelodysplastic syndromes: Prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts [letter] Blood 99 2002 3870 3871
6. E. Hellström-Lindberg Approach to anemia associated with myelodysplastic syndromes Curr Hematol Rep 2 2003 122 129
7. A.F. List New approaches to the treatment of myelodysplasia Oncologist 7 2002 39 49 (suppl 1)
8. D. Bowen, D. Culligan, S. Jowitt Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 2003 187 200
9. P. Fenaux Myelodysplastic syndromes: From pathogenesis and prognosis to treatment Semin Hematol 41 2004 6 12 (suppl 4)
10. E. Hellström-Lindberg, N. Gulbrandsen, G. Lindberg A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life Br J Haematol 120 2003 1037 1046
11. A.J.G. Jansen, M.-L. Essink-Bot, E.A.M. Beckers Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes Br J Haematol 121 2003 270 274
12. N. Casadevall, P. Durieux, S. Dubois Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, control trial Blood 104 2004 321 327
13. D.J. Weisdorf, M.M. Oken, G.J. Johnson Chronic myelodysplastic syndrome: Short survival with or without evolution to acute leukaemia Br J Haematol 55 1983 691 700
14. B.D. Cheson, J.M. Bennett, H. Kantarjian Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood 96 2000 3671 3674
15. P. Greenberg, C. Cox, M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 91:1100, 1998] Blood 89 1997 2079 2088
16. National Comprehensive Cancer Network (NCCN) Myelodysplastic Panel Members: NCCN practice guidelines: Myelodysplastic syndromes v1. 2005 http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf (accessed February 9, 2005)
17. C. Rosenfeld, A. List A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies Leukemia 14 2000 2 8
18. B. Quesnel, G. Guillerm, R. Vereecque Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression Blood 91 1998 2985 2990
19. M.L. Heaney, D.W. Golde Myelodysplasia N Engl J Med 340 1999 1649 1660
20. A.K. Gandhi, S. Naziruddin, D. Verhelle Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines J Clin Oncol 22 2004 587s (suppl 14S) (abstr 6618)
21. S.K. Horrigan, Z.H. Arbieva, H.Y. Xie Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31 Blood 95 2000 2372 2377
22. J. Boultwood, S. Lewis, J.S. Wainscoat The 5q- syndrome Blood 84 1994 3253 3260
23. W.T. Bellamy, L. Richter, D. Sirjani Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes Blood 97 2001 1427 1434
24. J.M. Bennett, D. Catovsky, M.T. Daniel Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 1982 189 199
25. D.F. Cella Quality of life outcomes: Measurement and validation Oncology (Huntingt) 10 1996 233 246